Psychemedics Corporation Stock

Equities

PMD

US7443752057

Healthcare Facilities & Services

Market Closed - Nasdaq 16:30:00 2024-04-26 EDT 5-day change 1st Jan Change
2.55 USD +0.39% Intraday chart for Psychemedics Corporation -0.78% -13.85%
Sales 2022 25.24M 34.5M Sales 2023 22.1M 30.21M Capitalization 17.17M 23.47M
Net income 2022 -1M -1.37M Net income 2023 -4M -5.47M EV / Sales 2022 1.05 x
Net cash position 2022 1.18M 1.61M Net Debt 2023 334K 457K EV / Sales 2023 0.79 x
P/E ratio 2022
-25.5 x
P/E ratio 2023
-4.09 x
Employees 116
Yield 2022
5.71%
Yield 2023
2.36%
Free-Float 69.33%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.39%
1 week-0.78%
Current month-12.97%
1 month-15.00%
3 months-19.56%
6 months+4.08%
Current year-13.85%
More quotes
1 week
2.54
Extreme 2.54
2.75
1 month
2.51
Extreme 2.51
2.93
Current year
2.51
Extreme 2.51
3.93
1 year
2.06
Extreme 2.06
5.59
3 years
2.06
Extreme 2.06
8.90
5 years
2.06
Extreme 2.06
12.15
10 years
2.06
Extreme 2.06
27.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-08-16
Director of Finance/CFO 34 11-26
Corporate Officer/Principal 38 23-09-20
Members of the board TitleAgeSince
Director/Board Member 62 22-08-11
Chairman 66 22-08-11
Director/Board Member 63 21-03-15
More insiders
Date Price Change Volume
24-04-26 2.55 +0.39% 655
24-04-25 2.54 -3.97% 7,121
24-04-24 2.645 +2.27% 1,395
24-04-23 2.586 -2.59% 964
24-04-22 2.655 +3.31% 2,119

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm

More quotes
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
More about the company